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Abstract
Low back pain is experienced by a large number of people 
in western countries and may be caused and influenced by 
many different pathologies and psychosocial factors includ-
ing disc degeneration. Disc degeneration involves the in-
creased expression of proinflammatory cytokines and matrix 
metalloproteinases (MMPs) in the disc environment, which 
leads to the loss of extracellular matrix (ECM) and the viabil-
ity of the native disc cells (DCs). Treatment approaches using 
growth factors and cell therapy have been proposed due to 
the compelling results that growth factors and mesenchy-
mal stem cells (MSCs) can influence the degenerated discs. 
The aim of this study was to investigate the effects of condi-
tioned media (CM) from human MSCs (hMSCs) and connec-
tive tissue growth factor (CTGF) and TGF-β on disc cells, and 
hMSCs isolated from patients with degenerative discs and 
severe low back pain. The aim was also to examine the con-
stituents of CM in order to study the peptides that could 
bring about intervertebral disc (IVD) regeneration. DCs and 
hMSC pellets (approx.. 200,000 cells) were cultured and stim-
ulated with hMSC-derived CM or CTGF and TGF-β over 28 
days. The effects of CM and CTGF on DCs and hMSCs were 
assessed via cell viability, proteoglycan production, the ex-
pression of ECM proteins, and chondrogenesis in 3D pellet 
culture. To identify the constituents of CM, CM was analyzed 
with tandem mass spectrometry. The findings indicate that 
CM enhanced the cellular viability and ECM production of 
DCs while CTGF and the control exhibited nonsignificant dif-
ferences. The same was observed in the hMSC group. Mass 
spectrometry analysis of CM identified > 700 peptides, 129 of 
which showed a relative abundance of ≥2 (CTGF among 
them). The results suggest that CM holds potential to coun-
ter the progression of disc degeneration, likely resulting 
from the combination of all the substances released by the 
hMSCs. The soluble factors released belong to different pep-
tide families. The precise mechanism underlying the regen-
erative effect needs to be investigated further, prior to incor-
porating peptides in the development of new treatment 
strategies for low back pain that is potentially caused by IVD 
degeneration. © 2020 The Author(s)
Published by S. Karger AG, Basel
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Attribution-NonCommercial-4.0 International License (CC BY-NC) 
(http://www.karger.com/Services/OpenAccessLicense), applicable to 
the online version of the article only. Usage and distribution for com-
mercial purposes requires written permission.
The Effect of hMSC CM on DCs 77Cells Tissues Organs 2019;208:76–88
DOI: 10.1159/000506350
Introduction
Low back pain is experienced by a large number of 
populations in the West where the lifetime prevalence 
is > 84% [Airaksinen et al., 2006]. Low back pain ranks 
higher than most fatal diseases in terms of years lived 
with disability according to the Global Burden of Dis-
ease Study [van Hooff et al., 2014]. The cause of low 
back pain is multifactorial in nature. In individuals with 
chronic low back pain, disc bulging and degenerative 
changes in the intervertebral discs (IVDs) have been 
shown to be more common [Brinjikji et al., 2015] than 
in control populations. Degenerative disc disease is as-
sociated with long-standing severe back pain. The ar-
chitecture of the IVD involves 2 main tissues, the an-
nulus fibrosus (AF) and the nucleus pulposus (NP).The 
AF is the thick lamellae ring made up of organized col-
lagen fibers that surround the gelatinous structure of 
the NP within the end plates [Humzah and Soames, 
1988]. The NP is made up of proteoglycan and collagen, 
crucial for the water content of the IVDs [Roughley, 
2004]. The AF is mainly populated by fibroblast-like 
cells while chondrocyte-like cells inhabit the NP [Ad-
ams and Roughley, 2006; Minogue et al., 2010]. In de-
generated discs, the collagen fibers in the tissue be-
comes gradually more and more disorganized, and the 
2 tissues become hard to distinguish from each other 
[Adams and Roughley, 2006]. Increased expression of 
proinflammatory cytokines and matrix metalloprotein-
ases (MMPs) in degenerated IVDs leads to a loss of pro-
teoglycan and extracellular matrix (ECM), affecting the 
viability of the disc cells (DCs) in the IVDs [Ekman et 
al., 2005; Airaksinen et al., 2006]. Current surgical treat-
ments are symptomatic and do not tackle the degenera-
tive process or promote regeneration [Phillips et al., 
2013]. Thus, new treatment strategies with effective 
therapeutic agents that can be clinically applied as a 
minimally invasive regenerative therapy are warranted. 
Several treatment approaches for degenerated disc dis-
ease, including growth factors and cell therapy, have 
been suggested [Peroglio et al., 2013; Zeckser et al., 
2016]. Growth factors such as transforming growth fac-
tor β (TGF-β) and connective tissue growth factor 
(CTGF) have been reported as major focal points in 
protein interaction networks that act as the main in-
ducer of chondrogenesis. In fact, in vitro stimulation 
with these factors demonstrated enhanced cell prolif-
eration and ECM production in rat-tail disc cells [Mat-
ta et al., 2017]. Meanwhile, cell therapy with mesenchy-
mal stem cells (MSCs) also show promise in promoting 
regenerative effects in many disease models [Gou et al., 
2014; Somoza et al., 2014]. It has been reported that 
transplanted cells do not survive for long, but the ther-
apeutic effect observed was due to the vast array of bio-
active substances secreted by the cells that played an 
important role in regulating key biological processes 
[Vizoso et al., 2017]. DCs have previously been report-
ed to have regenerative outcomes when cocultured with 
human (h)MSCs, indicating that substances secreted 
from hMSCs might have therapeutic potential [Svanvik 
et al., 2010; Hingert et al., 2020]. Studies have also 
shown that conditioned media (CM) derived from 
MSCs promotes tissue repair in arthritis and cartilage 
models [Toh et al., 2014; Kay et al., 2017]. 
All these reports provide compelling evidence that 
growth factors (CTGF and TGF-β) and/or proteins se-
creted from MSCs may have the ability to restore the in-
tegrity of the discs and/or arrest degeneration processes. 
To validate this hypothesis, the aim of this study was to 
compare the effects of CM from hMSCs with the effects 
of the growth factors CTGF and TGF-β on DCs and hM-
SCs isolated from patients with low back pain in a 3D in 
vitro model. The aim was to further identify the constitu-
ents of CM to gain an insight into the network of proteins 
secreted by the hMSCs.
Materials and Methods
Patients
Disc tissues and bone marrow aspirates (BMA) from the iliac 
crest were collected from patients with long-standing low back 
pain without radicular pain, who had been diagnosed with degen-
erated-disc disease and were undergoing spinal fusion surgery in-
cluding the removal of the disc(s). The discs were graded according 
to the Pfirrmann grading system on magnetic resonance imaging 
(MRI) as grade 3/4. Disc tissue was obtained from the center of the 
disc. However, the obtained tissue was a mixture of AF and NP tis-
sue due to the disintegration of the discs. Due to limited samples, 
no characterization of the cells was performed. Both disc tissues 
and BMA were obtained from 2 females and 1 male donor aged 
29—49 years.
DC Isolation and Cell Culture
Disc tissues were cut into small pieces, transferred to culture 
flasks (CORNING, NY, USA), and incubated with 1 mg/mL type 
II collagenase at 37  ° C and 5% CO2 overnight. Cell suspensions 
were centrifuged at 1,500 rpm for 5 min and the cells were there-
after cultured at 37  ° C and 5% CO2 in DC medium (DMEM-low 
glucose with 110 mg/L sodium pyruvate, 4 mmol/L L-glutamine 
[Thermo Fisher Scientific, MA, USA], and 1% penicillin/strepto-
mycin, and supplemented with 10% human serum albumin 
[HSA]). The medium was changed every 48 h and the DCs were 
passaged at 90% confluency. All DCs used in the study were in pas-
sage 5.
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hMSC Isolation and Cell Culture
BMA collected in 3.2% sodium citrate (Greiner Bio One, 
Kremsmuenster, Austria) were transferred to a Ficoll tube (BD Va-
cutainer® CPTTM, Biosciences, NJ, USA) and centrifuged at 1,500 
rpm for 20 min. hMSCs were isolated and cultured at 37  ° C and 
5% CO2 in MSC media (DMEM low glucose with 110 mg/L sodi-
um pyruvate and 4 mmol/L L-glutamine [Thermo Fisher Scien-
tific]), together with 1% penicillin/streptomycin, 10% HSA, and 4 
ng/mL β-fibroblast growth factor (FGF). The medium was changed 
every 48 h and cell passaging was done at 90% confluency. All 
hMSCs used in the study were in passage 5.
Collection of hMSC CM
hMSCs from 3 patients were cultured in MSC media at a den-
sity of approximately 10,000 cells/cm2 for 14 days, and CM was 
harvested every 48 h. The collected CM was centrifuged at 1,500 
rpm at 4  ° C for 5 min. The supernatants (from all 3 patients) were 
then pooled, sterile-filtered (SARSTEDT, Nümbrecht, Germany), 
and stored at –80  ° C until further use. All the hMSCs used in the 
study were in passage 4–5.
3D Pellet Culture
Approximately 200,000 DCs or hMSCs were distributed into 
each conical tube with 0.5 mL of relevant medium, centrifuged at 
1,500 rpm at 4  ° C for 5 min, and then incubated at 37  ° C and 5% 
CO2. The medium was changed every 2–3 days and the pellets were 
harvested on days 7, 14, and 28. The experiments were conducted 
separately with each cell type from each donor. 
Pellet Stimulation
DC pellets were stimulated with CM (CM in chondrogenic me-
dia at a 1: 1 ratio) or 10 ng/mL CTGF (R&D Systems, MN, USA) in 
chondrogenic media (DMEM high glucose with insulin, transfer-
rin, and selenium [ITS-G; Thermo Fisher Scientific], 5 mg/mL lin-
oleic acid, 10 ng/mL TGF-β1; R&D Systems), 14 mg/mL ascorbic 
acid , 10–7 M dexamethasone [Sigma-Aldrich, MS, USA], 1.0 mg/
mL HSA [Equitech-Bio Inc., KV, USA] and 1% penicillin/strepto-
mycin) (Fig. 1a). As the hMSCs were able to produce the same fac-
tors that are in CM, hMSC pellets were only stimulated with 10 ng/
mL CTGF. Chondrogenic medium (contains TGF-β) without any 
additives served as a control group. Four replicates of pellets were 
cultured for each stimulation group per donor (i.e., 12 pellets in 
total for each stimulation group), where 2 pellets were used for 
histological evaluation and 2 for the biochemical analysis of each 
stimulation group.
Cell Proliferation/Viability Measurement
50 µL of cell-counting kit 8 (CCK-8) solution (Dojindo, Mu-
nich, Germany) was added to each pellet and incubated for 4 h at 
37  ° C and 5% CO2. The supernatant was then collected, and the 
color intensity measured at 450 nm with a microplate reader 
(BioTek, VT, USA). CCK-8 assay was performed on days 7, 14, and 
28 before harvesting the pellets. The supernatant was collected in 
duplicate from 4 pellets for each stimulation group (i.e., 8 repli-
cates/stimulation group). 
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Fig. 1. a Schematic illustration of different stimulations used on hMSC and DC pellets. Illustration of cell viabil-
ity and proliferation on days 7–28 in DC pellets treated with conditioned media (CM) and 10 ng/mL CTGF 
(CTGF) (b) and hMSC pellets treated with 10 ng/mL CTGF (CTGF) (c). Values are mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Histological Staining
DC and hMSC pellets were fixed with 4% formaldehyde (His-
tolab products, Gothenburg, Sweden), sectioned, and then stained 
with Alcian blue van Gieson. The histology sections were later ex-
amined for proteoglycan and collagen deposition on light micros-
copy (Nikon Eclipse E600). This was conducted on 2 sections from 
each of the 2 pellets for both cell types (i.e., 4 sections investigated/
stimulation group).
Glycosaminoglycan and DNA Assays
The pellets were digested with papain (1.5 mg papain/mL [Sig-
ma-Aldrich, MS, USA]), 20 mM sodium phosphate buffer, 1 mM 
EDTA, and 2 mM dithiothreitol prior to incubation at 60  ° C over-
night. Glycosaminoglycan (GAG) and DNA were quantified with 
the glycosaminoglycans assay kit (Chondrex, WA, USA) and the 
DNA assay kit (Chondrex), respectively. The GAG and DNA con-
tent was then measured at 525 nm and an excitation of 360 nm/
emission 460 nm for GAG and DNA, respectively, with a micro-
plate reader (BioTek). The analysis was conducted in 4 replicates 
for each stimulation group, and GAG content was normalized to 
the total amount of DNA in each pellet.
Immunohistochemistry
Immunohistochemistry was carried out to verify the character-
istics of chondrocyte-like cells in the DCs and chondrogenic dif-
ferentiation in the hMSCs. The expression of keratin-19 (KRT19), 
aggrecan (ACAN), and collagen type II (COLIIA1) was studied in 
DC pellets, and the expression of Sox9, ACAN, and COLIIA1 in 
hMSC pellets. Briefly, paraffin-embedded sections were deparaf-
finized and rehydrated; antigen retrieval (citrate buffer, pH 6, 
90  ° C for 20 min) was then carried out. Primary antibodies used 
include anti-KRT19 (1: 100), anti-Sox9 (1: 1,000), anti-ACAN (1: 
500), and anti-COLIIA1 (1: 100, Abcam, Cambridge, MA, USA). 
After incubation at 4  ° C overnight, the sections were blocked with 
blocking solution (0.1% Triton X-100, 2% BSA, and 100 mM gly-
cine in PBS). COLIIA1 sections only were blocked with 3% BSA. 
Secondary antibodies include donkey anti-rabbit IgG Alexa Fluor 
546 (1: 200, Thermo Fisher Scientific) against KRT19, Sox9, and 
ACAN, and goat anti-rabbit IgG Alexa Fluor 546 (1: 200, Thermo 
Fisher Scientific) against COLIIA1. To complement the detection 
of COLIIA1, the sections were incubated with SA-HRP (1: 100, 
TSA plus cyanine 3 system kit, PerkinElmer, MA, USA) for 30 min, 
and cyanine 3 tyramide (1: 100, TSA plus cyanine 3 system kit) 
prior to nuclei counterstaining with ProLong® gold antifade 
mountant (DAPI; Thermo Fisher Scientific). The samples were ex-
amined under fluorescence microscope (Nikon Eclipse E600, Ja-
pan). NIS Elements software (Nikon Metrology NV, Europe) was 
used to perform fluorescence intensity quantification and deter-
mine the area of the pellets. The levels of protein expression were 
presented as pixel/µm2. The analysis was conducted in 4 replicates 
for each stimulation group. 
CM Preparation for Secretome Analysis
Proteins in CM were digested using the filter-aided sample 
preparation (FASP) method [Wiśniewski et al., 2009]. Briefly, pro-
tein samples were concentrated using 30 kDa MWCO Pall Nanosep 
centrifugal filters (Sigma-Aldrich). Digestion was performed in 50 
mM TEAB and 1% sodium deoxycholate (SDC) overnight at 37  ° C 
after the addition of trypsin (Pierce trypsin protease, MS grade, 
Thermo Fisher Scientific) in a ratio of 1: 100 relative to the amount 
of protein. Digested peptides were labeled using TMT 10-plex iso-
baric mass tagging reagents (Thermo Scientific) according to the 
manufacturer’s instructions. MSC medium served as a control.
Mass Spectrometry Analysis
Liquid chromatography-mass spectrometry analysis was per-
formed by the Proteomics Core Facility, Sahlgrenska Academy, 
Gothenburg University. Mass spectrometric analysis was per-
formed with a Q Exactive mass spectrometer (Thermo Fisher Sci-
entific). Briefly, the CM was analyzed for its peptide content and 
compared to control medium. Samples were fractioned into 40 
fractions based on hydrophobicity, in order to increase analytical 
resolution. Tandem-mass tags (TMT) were used to quantify the 
relative amounts of peptides in the CM compared to the control 
media. Data analysis was performed utilizing Proteome Discov-
erer v1.4 (Thermo Fisher Scientific) against the Human Swissprot 
Database version March 2015 (Swiss Institute of Bioinformatics, 
Switzerland). Mascot 2.3.2.0 (Matrix Science) was used as a search 
engine. Ratio and fold-changes were calculated by using control 
(MSC) media as a denominator. Identified peptides were grouped 
based on literature findings.
Statistical Analysis
All statistical data are presented as the mean ± standard error 
of the mean (SEM). Data were analyzed via SPSS v25.0 software 
(IBM SPSS Statistics, NY, USA). Two-tailed Student’s t test was 
used for CCK-8 and GAG assays, as well as fluorescence intensity 
quantification for hMSC groups (comparing the means of 2 
groups) while ANOVA with the Tukey post hoc test was used for 
that of DC groups (multiple comparisons). p < 0.05 was considered 
statistically significant.
Results
Cell Proliferation/Viability Measurement
In DC pellets, the CM stimulated group demonstrated 
a continuous cell proliferation on days 7—28, and the 
number of viable cells was significantly higher than in the 
CTGF group at 2 time points, i.e., day 14 (p < 0.05) and 
day 28 (p < 0.001) (Fig. 1b). However, there was no sig-
nificant difference between the CTGF and control groups. 
The cell viability of hMSC pellets was highest on day 7 for 
both the CTGF and control groups, compared to the oth-
er time points. Nevertheless, throughout the experiment, 
the CTGF group showed no significant difference from 
controls (p > 0.05) (Fig. 1c). 
Histological Staining
Alcian blue van Gieson staining was carried out to ex-
amine proteoglycan and collagen deposition within the 
cell pellets. In DC pellets, compared to the other groups, 
CM demonstrated the highest proteoglycan accumula-
tion at all time points, starting on day 7 and being main-
tained until day 28 (Fig.  2a). The CTGF and control 
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groups revealed no proteoglycan accumulation in DC 
pellets. However, collagen deposition was observed. For 
the hMSC pellets, CTGF stimulation demonstrated pro-
teoglycan accumulation on days 7 and 14. A similar pat-
tern was observed in the control group (Fig. 2b). 
Glycosaminoglycan and DNA Assays
In DC pellets, CM yielded the highest GAG produc-
tion at all time points and the levels were significantly 
higher on day 7 (p < 0.01) and day 28 (p < 0.001) com-
pared to the CTGF and control groups (Fig. 2c). In hMSC 
pellets, GAG production gradually increased from day 7 
to day 28, but no significant difference was observed be-
tween the CTGF and control groups (p > 0.05) (Fig. 2d). 
Immunohistochemistry
KRT19
The expression of KRT19 protein was observed in DC 
pellets at all time points regardless of the stimulations 
(Fig. 3a), confirming the chondrocyte-like cell properties 
of DC in the experiment. There was, however, no signifi-
cant difference between the groups (Fig. 3c).
Sox9
The expression of Sox9 protein was observed in hMSC 
pellets as early as day 7, and the expression was elevated 
at later time points for both the CTGF stimulated and 
control groups (Fig. 3b, d), indicating the occurrence of 
chondrogenesis.
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Aggrecan
In DC pellets, significantly higher expression of ACAN 
was observed in pellets treated with CM. An increase in 
expression was detected with time compared to in the 
CTGF and control groups. No significant difference was 
observed between the CTGF and control groups (Fig. 4a, 
c). Similarly, the expression of ACAN protein was ob-
served in hMSC pellets at all time points, with no signifi-
cant difference between CTGF and control groups 
(Fig. 4b, d). 
COLIIA1
In DC pellets, significantly higher COLIIA1 expres-
sion was found in the CM group on days 14 and 28, 
whereas CTGF showed low COLIIA1 expression and was 
not significantly different from the control (Fig.  5a, c). 
Although COLIIA1 expression was detected at all time 
points in hMSC pellets (Fig. 5b), the expression was rela-
tively low with no significant difference in the CTGF and 
control groups (Fig. 5d). 
Mass-Spectrometry Analysis of CM
Mass spectrometry analysis identified 753 unique pep-
tides present in CM; 129 of these showed a relative abun-
dance (CM/MSC media) of ≥2, and 275 peptides showed 
< 2 (for a complete list of proteins, see online suppl. Table 
1; for all online suppl. material, see www.karger.com/
doi/10.1159/000506350). The 129 peptides comprised 
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ECM protein, enzymes, growth factors, tissue inhibitors 
of metalloproteinase 1 (TIMP-1), MMPs, MMP regula-
tors, transporters, etc. (Fig. 6). Among the growth factors, 
vascular endothelial growth factor (VEGF), bone mor-
phogenetic protein-1 (BMP-1) and CTGF were identified 
(Table 1). 
Discussion
The findings in this study demonstrated that the stim-
ulation of DCs with CM enhanced cellular viability as 
well as promoting ECM production, crucial for main-
taining the structural integrity and biomechanical prop-
erties of the spine. The stimulation with CTGF did not 
add to the normal effect of chondrogenic media (con-
taining TGF-β), in promoting chondrogenesis in either 
hMSCs or DCs, and was less effective than the hMSC 
CM. 
Disc tissues collected from patients were a mixture of 
AF and NP due to disintegration of the discs; this made 
it difficult to distinguish between AF and NP. Suggest- 
ed markers for chondrocyte-like/NP cells are ACAN, 
COLIIA1, KRT19, NCAMI, etc. [Minogue et al., 2010; 
Rutges et al., 2010; Risbud et al., 2015; Tang et al., 2016]. 
KRT19, ACAN, and COLIIA1 expression in DC pellets 
confirmed the chondrocyte-like cell characteristic of the 
DCs isolated. One of the limitations of the study was that 
no characterization of the cells in the disc tissues was per-
formed to determine the ratio of AF and NP cells in these 
experiments due to limited sample availability. Sox9, 
ACAN, and COLIIA1 expression in hMSC pellets vali-
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dated the chondrogenic differentiation of the hMSCs 
[Chimal-Monroy et al., 2003]. 
Mass spectrometry analysis revealed 129 secreted pep-
tides, which included modulators of growth factors, anti-
apoptotic factors, antiangiogenic factors, MMP inhibitors, 
and several proteoglycans including collagens and small 
leucine-rich proteoglycans (SLRPs). CTGF was among the 
growth factors identified. It is known as a vital component 
of the IVD microenvironment where it interacts with sev-
eral growth factors and ECM proteins [Abreu et al., 2002; 
Leask and Abraham, 2006; Nishida et al., 2007; Tran et al., 
2010]. Like TGF-β, CTGF plays a role in the development 
of cartilage and IVD in the embryonic stage of the spine [Jin 
et al., 2011]. The different domains in CTGF mediate phys-
ical interaction with bone morphogenetic proteins (BMPs) 
and TGF-β ligands. The interaction is assisted by growth 
factor modulators such as insulin-like growth factor (IGF)-
binding proteins, latent TGF-β-binding protein 3, fol-
listatin, decorin, and EMILIN-1 [Abreu et al., 2002; Leask 
and Abraham, 2006; Munjal et al., 2014]. BMP-1, a member 
of the TGF-β superfamily that interacts with CTGF, along 
with VEGF, a growth factor that promotes cartilage repair 
and regeneration [Gugjoo et al., 2016; Schorn et al., 2017; 
Vadalà et al., 2018], was also identified. These protein net-
works illustrate the complexity of the signaling mecha-
nisms required to maintain a healthy IVD. 
Even though CM was supplemented with chondrogenic 
media containing TGF-β (at a 1: 1 ratio; Fig. 1), the concen-
tration of TGF-β might have been lower than that in the 
CTGF and control groups. However, stimulation with CM 
resulted in greater cell proliferation and ECM production 
than in the CTGF and control groups in DC pellets. Detec-
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tion of significantly higher cell proliferation in DCs could 
be triggered synergistically by the growth factors, the ECM, 
and the plasma proteins in the CM. VEGF, BMP-1, and 
CTGF are known to promote proliferative activities [Kim 
et al., 2012]. Several ECM and plasma proteins, such as 
EGF-containing fibulin-like extracellular matrix protein 2 
and prosaposin, regulate cell proliferation, while stannio-
calcin-1 acts as an antiapoptotic factor in response to the 
activation by apoptotic cells [Misasi et al., 2004; Block et al., 
2009; Sun et al., 2010]. This may account for the increased 
viability observed in DCs when stimulated with CM. 
CM induced significantly higher proteoglycan accumu-
lation and GAG production, and it displayed higher expres-
sion of ACAN and COLIIA1 in DCs than in the CTGF and 
control groups. These findings are supported by previous 
findings that MSCs elevated ACAN and COLIIA1 expres-
sion and CM lowered ACAN degradation in a murine mod-
el of arthritis [Kay et al., 2017; Soetjahjo et al., 2018]. The 
observed effects of CM could possibly be caused by the pres-
ence of growth factors and several ECM proteins (cathep-
sin, peroxidasin, urokinase-type plasminogen activator, 
and plasminogen activator inhibitor-1, which are involved 
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in ECM assembling, remodeling, and modification [Camp-
bell et al., 1991; Péterfi et al., 2009; Bonnans et al., 2014; Mao 
et al., 2014; Popa et al., 2014]. The multiple proteins in CM 
most likely worked hand in hand to bring about the chon-
drogenic effects observed in this study.
In addition, the presence of angiopoietin-related pro-
tein 4, an antagonist of Wnt-signaling in CM, may have 
been beneficial as the Wnt-signaling pathway regulates 
the expression of proinflammatory cytokines involved in 
IVD degeneration [Hiyama et al., 2013]. Metalloprotein-
ase inhibitor-1, that can combat the activities of MMPs, 
was also identified. However, more investigations into 
these factors are needed to elucidate the exact role they 
play in combating IVD degeneration. 
Other proteins such as semaphorin, nidogen-2, and 
olfactomedin-like protein 3 were also identified and their 
exact role remains unknown [Matta et al., 2017]. How-
ever, semaphorin is reported to be a key regulator of a 
specific signaling mechanism through several receptor 
complexes essential for cell migration, morphology, and 
motility [Casazza et al., 2007; Alto and Terman, 2017]. 
Semaphorin has been demonstrated to be highly ex-
pressed in healthy DCs [Alto and Terman, 2017].  
Stimulation with CTGF in this study had no significant 
effect on DC and hMSC proliferation compared to the con-
trol group as we have hypothesized, implying that CTGF 
was not solely responsible for the effect seen by CM even 
in the presence of TGF-β. Furthermore, the concentration 
Table 1. Representative list of proteins identified in CM of hMSCs along with their classes and functions
No. Accession No. Name Class Function
1 P49767 Vascular endothelial growth factor growth factor involved in cartilage repair and regeneration
2 P13497 Bone morphogenetic protein 1 growth factor cartilage proliferation and collagen synthesis
3 P29279 Connective tissue growth factor growth factor cartilage and bone development
4 P22692 Insulin-like growth factor-binding
protein
growth factor 
modulator
regulates CTGF
5 Q9NS15 Latent-transforming growth factor
β-binding protein 3
growth factor 
modulator
key regulator of TGF-β
6 P09382 Galectin-1 growth factor 
modulator
suppresses proinflammatory cytokine synthesis
7 P19883 Follistatin protein inhibitor regulates TGF-β
8 P05121 Plasminogen activator inhibitor 1 protein inhibitor involved in cartilage repair
9 Q9BY76 Angiopoietin-related protein 4 precursor protein Wnt signaling antagonist
10 P07602 Prosaposin precursor protein regulates cell proliferation and apoptosis
11 O95967 EGF-containing fibulin-like
extracellular matrix protein 2
ECM protein regulates cell proliferation and apoptosis
12 Q92626 Peroxidasin ECM protein plays a role in ECM modification
13 Q14112 Nidogen-2 ECM glycoprotein involved in ECM assembly and cell invasion
14 Q9NRN5 Olfactomedin-like protein 3 ECM glycoprotein binds to BMP-4 and involved in angiogenesis
15 Q9Y6C2 EMILIN-1 ECM glycoprotein negatively regulates TGF-β signaling
16 P52823 Stanniocalcins plasma protein antiapoptotic factor
17 O75326 Semaphorin transmembrane 
protein
inhibits angiogenesis and nerve in-growth in IVDs
18 P07585 Decorin proteoglycan negatively regulates TGF-β signaling
19 P01033 Metalloproteinase inhibitor 1 TIMP-1 inhibitor of MMP-1
20 P00749 Urokinase-type plasminogen activator enzyme involved in angiogenesis and cartilage remodeling
21 P07339 Cathepsin D enzyme ECM remodeling 
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used in this study might have been too low. The concentra-
tion of 100 ng/mL of CTGF has been reported to promote 
cell viability in the monolayers of NP cells [Matta et al., 
2017] and articular chondrocytes [Xing et al., 2018]. How-
ever, the motivation for using 10 ng/mL CTGF here was 
that chondrogenic/control medium contained 10 ng/mL 
TGF-β, which has been reported to induce the expression 
of CTGF [Kothapalli et al., 1997; Chen et al., 2000]. CTGF 
at 5 ng/mL has also been shown to coordinate ECM syn-
thesis in the presence of TGF-β [Wu et al., 2018]. The no-
tion behind not testing hMSC pellets with CM was that the 
hMSCs could produce their own secretome, and that 
CTGF should boost proliferation and chondrogenesis. The 
fact that CM was effective on DCs implies that the secre-
tome was perhaps meant for other cell types [Baraniak and 
McDevitt, 2010]. CM from other cell types has also been 
reported to show regenerative effects [Bach et al., 2016]. 
The presence of complex protein networks in the CM ex-
plains why a therapeutic effect was observed in coculture 
models. Enhanced chondrogenic activity was previously 
reported in cocultured DCs and hMSCs, and it was be-
lieved to be due to cell-to-cell communication or the secre-
tion of substances through paracrine signaling [Svanvik et 
al., 2010; Hingert et al., 2020]. In addition to signaling pep-
tides, hMSCs are reported to secrete extracellular vesicles, 
including exosomes that act as vehicles transporting vari-
ous biological factors to targeted cells [Cheng et al., 2018]. 
These exosomes have been reported to have regenerative 
effects on disc degeneration [Bach et al., 2016]; however, 
further investigations are needed. 
In conclusion, CM holds the potential to influence DCs 
from degenerated discs. The therapeutic effect observed 
was most probably caused by a combination of all the sub-
stances released by the hMSCs (not just by the growth fac-
tors, e.g., CTGF and TGF-β). These signaling peptides be-
long to different peptide families. The identification of the 
key factors needs to be carried out before suggesting pep-
tide combinations should be used as a new treatment 
strategy for IVD degeneration that leads to low back pain.
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